Blueprint Medicines Corporation (BPMC) es una empresa que cotiza en bolsa en el Salud sector, operando dentro de la Biotecnología industria. La empresa tiene su sede en Cambridge, MA, United States. El CEO actual es Kathryn Haviland.
BPMC tiene fecha de IPO 2015-04-30, 682 empleados a tiempo completo, cotiza en el NASDAQ Global Select, una capitalización de mercado de $8.36B.
Blueprint Medicines Corporation is a precision therapy company that develops targeted medicines for genomically defined cancers and blood disorders globally. The company's marketed and pipeline products include AYVAKIT and BLU-263 for systemic mastocytosis and mast cell disorders, GAVRETO for RET fusion-positive cancers, Fisogatinib for hepatocellular carcinoma, and several investigational therapies targeting EGFR mutations in non-small-cell lung cancer, as well as rare genetic disorders. Blueprint maintains strategic collaborations with leading pharmaceutical partners including Genentech, Roche, CStone Pharmaceuticals, and Zai Lab to advance its precision medicine pipeline. Founded in 2008 and headquartered in Cambridge, Massachusetts, the company is committed to delivering transformative treatments for patients with serious diseases driven by specific genetic alterations.
